WHO's Product Recall Order For Shantha Biotech's Vaccine Puts Sanofi Aventis In Crisis Management Mode; Vows To Resume Supplies By End Of 2010
This article was originally published in PharmAsia News
MUMBAI - French drug maker Sanofi Aventis is faced with an unexpected crisis situation over large quantities of product recall ordered by the World Health Organization for pediatric pentavalent vaccines manufactured by its newly acquired Indian vaccines unit - Shantha Biotechnics
You may also be interested in...
The Indian subsidiary of French drug maker Sanofi-Aventis has been told by the United Nations it was suspending purchase and use of the Shan5 vaccine for five diseases, including tetanus
MUMBAI - Shantha Biotechnics - the Indian biotech acquired by Sanofi-Aventis - has bagged a $340 million contract from the World Health Organization for supply of the pentavalent vaccine branded SHAN5 over a period of two years starting 2010. The vaccine indigenously developed by Shantha immunizes children against diphtheria, pertussis, tetanus, hemophillus influenza B and hepatitis B
MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India